LUX Lung 2 clinical trial infographic

Boehringer Ingelheim

LUX-Lung 2 is a multicentre Phase II, randomised, open-label, single arm trial of afatinib* in patients with advanced lung cancer that were untreated or progressed after one course of chemotherapy. Patients were tested for activating EGFR mutations prior to their inclusion in the trial. 129 male and female patients took part in the LUX-Lung 2 trial.

The primary endpoint was objective response rate (ORR). The secondary endpoints were Progression-free survival (PFS), Disease control rate (DCR) and Overall survival (OS).

Patients with the activating EGFR mutations (del 19 and L858R) showed high response rates and remarkable progression-free survival rates when treated with afatinib*.

*Afatinib (compound code BIBW 2992) is an investigational compound. Its safety and efficacy has not yet been fully established.

1. Yang et al. A Phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-Lung 2). Poster presentation at the 35th European Society of Medical Oncology (ESMO) annual meeting, Milan, October 2010. Abstract ID: 367PD

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on